Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Miscasts “Dietary Substance” In Statements On DSHEA – Petition

This article was originally published in The Tan Sheet

Executive Summary

FDA's recently articulated interpretation of what constitutes a dietary substance "would substantially narrow the scope of the statutory definition of a dietary supplement," according to an April 8 citizen petition by supplement trade groups and companies

You may also be interested in...



NPA Dusts Off DSHEA Coalition To Expand Industry’s Political Clout

NPA is restarting the Coalition to Preserve DSHEA on its own and other supplement industry trade groups are welcome to join. “We’re going to pick up the pace and really work to gain access the way other FDA-regulated industries do,” says NPA President Daniel Fabricant.

NPA Dusts Off DSHEA Coalition To Expand Industry’s Political Clout

NPA is restarting the Coalition to Preserve DSHEA on its own and other supplement industry trade groups are welcome to join. “We’re going to pick up the pace and really work to gain access the way other FDA-regulated industries do,” says NPA President Daniel Fabricant.

FDA Warning Draws Solid Line Between Steroid Products And Supplements

FDA's enforcement approach toward a firm warned about marketing synthetic steroids as dietary supplements represents a more watertight legal strategy than the agency has used in similar scenarios

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel